Drug Profile
Estradiol transdermal - Merck KGaA
Alternative Names: Fem7; Feminova; Femsept; FemSeven; FemsevenLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck KGaA
- Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Menopausal syndrome; Postmenopausal osteoporosis
Most Recent Events
- 31 Dec 2002 Fem7® has been licensed to Gedeon Richter in many Central European, Eastern European and Commonwealth of Independent States countries
- 31 Dec 1998 Launched for Menopausal syndrome in Europe (Transdermal)
- 31 Dec 1998 Launched for Menopausal syndrome in Latin America (Transdermal)